The state of complement in COVID-19

Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Afzali, Behdad, Noris, Marina, Lambrecht, Bart N., Kemper, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Progress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672651/
https://www.ncbi.nlm.nih.gov/pubmed/34912108
http://dx.doi.org/10.1038/s41577-021-00665-1
_version_ 1784615397898584064
author Afzali, Behdad
Noris, Marina
Lambrecht, Bart N.
Kemper, Claudia
author_facet Afzali, Behdad
Noris, Marina
Lambrecht, Bart N.
Kemper, Claudia
author_sort Afzali, Behdad
collection PubMed
description Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.
format Online
Article
Text
id pubmed-8672651
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86726512021-12-15 The state of complement in COVID-19 Afzali, Behdad Noris, Marina Lambrecht, Bart N. Kemper, Claudia Nat Rev Immunol Progress Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19. Nature Publishing Group UK 2021-12-15 2022 /pmc/articles/PMC8672651/ /pubmed/34912108 http://dx.doi.org/10.1038/s41577-021-00665-1 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Progress
Afzali, Behdad
Noris, Marina
Lambrecht, Bart N.
Kemper, Claudia
The state of complement in COVID-19
title The state of complement in COVID-19
title_full The state of complement in COVID-19
title_fullStr The state of complement in COVID-19
title_full_unstemmed The state of complement in COVID-19
title_short The state of complement in COVID-19
title_sort state of complement in covid-19
topic Progress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672651/
https://www.ncbi.nlm.nih.gov/pubmed/34912108
http://dx.doi.org/10.1038/s41577-021-00665-1
work_keys_str_mv AT afzalibehdad thestateofcomplementincovid19
AT norismarina thestateofcomplementincovid19
AT lambrechtbartn thestateofcomplementincovid19
AT kemperclaudia thestateofcomplementincovid19
AT afzalibehdad stateofcomplementincovid19
AT norismarina stateofcomplementincovid19
AT lambrechtbartn stateofcomplementincovid19
AT kemperclaudia stateofcomplementincovid19

Ejemplares similares